BOSTON, June 13, 2017 /PRNewswire/ -- Cambridge Biomedical, a leading provider of customized assays for small and large molecules, biomarkers and diagnostics, has announced the appointment of Linda Robbie, Ph.D., as vice president of scientific affairs.
To view Linda's credentials: https://www.linkedin.com/in/linda-robbie-a3b93b4/
"We're thrilled to have Linda join our team," said Brad Yount, Cambridge Biomedical president and chief operating officer. "Her remarkable achievements, expertise and leadership experience will be an asset to the Cambridge Biomedical organization and reinforces our commitment to providing scientific leadership, cutting-edge assays and exceptional service to our clients."
As vice president of scientific affairs, Robbie will be a key member of the leadership team. She will direct all initiatives related to science and technology and the introduction of new products and services, serving as the scientific expert and interfacing with both clients and internal teams.
Before joining Cambridge, Robbie served as global senior director of the biomarkers and translational science laboratory at Q2 Solutions Laboratories, a Quintiles-Quest Joint Venture, and as senior director of the global assay development laboratory at Quintiles Laboratories. She was a research fellow at the University of Aberdeen and, after receiving the British Society for Hematology Research Fellowship, served as a research fellow at Harvard Medical School in Boston.
Robbie received a bachelor's degree with honors in biochemistry from Heriot-Watt University, Edinburgh, Scotland, and a Ph.D. in medical sciences from the Institute of Medical Science, Aberdeen University, Scotland.
About Cambridge Biomedical
Cambridge Biomedical, based in Boston, Mass., supports sponsors by developing customized assays for small and large molecules, biomarkers and other critical analytes, along with validation and sample testing in CLIA-certified and CAP-accredited, GLP/GCLP-compliant facilities. Cambridge has extensive expertise in assay development, optimization and validation, and offers analytical support for PK/PD studies, biomarker development, clinical assay development, assay validation, specimen analysis and testing services. For more information, visit the website at www.cambridgebiomedical.com, email firstname.lastname@example.org or call 617.456.0700.
Director of Sales
SOURCE Cambridge Biomedical